GUILDFORD, United Kingdom,
Jan. 8, 2015 /PRNewswire/ -- ANGLE
plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is
delighted to announce that it has agreed a collaboration with a
subsidiary of a large pharmaceutical company (the "Collaborator")
to investigate the combination of ANGLE's Parsortix circulating
tumour cell (CTC) harvesting platform with the Collaborator's
single cell analysis system.
The Collaborator Group is a multinational pharmaceutical,
biotechnology and diagnostics company with multi-billion dollar
revenues. The name of the Collaborator and other terms of the
collaboration are not disclosed.
The Collaborator's cell analysis system is best deployed on
sub-populations of cells that have been pre-enriched (concentration
of target cells and reduction of non-target cells such as white
blood cells). The Collaborator wishes to evaluate the use of
the Parsortix system as a standard pre-enrichment system for their
single cell analysis system. ANGLE's key opinion leaders have
previously reported that the Parsortix system harvests a high
purity of CTCs and was 30 times purer than a leading antibody-based
system. The first phase is a proof-of-principle of the
Collaborator's system working with Parsortix.
ANGLE's patented Parsortix system can harvest very rare
circulating tumour cells (CTCs) in cancer patient blood – even when
there is less than one CTC in one billion healthy cells. The
aim of the resulting liquid biopsy (simple blood test) is to enable
the investigation of mutations in the patient's cancer for
personalised cancer care. The Parsortix system is
"open-source" and has been designed to work with all existing
analytical procedures in the same way that the existing solid
biopsy provides cancer cells for a wide variety of analytical
procedures.
ANGLE's commercialisation strategy is to establish a series of
partnerships with multiple leading diagnostic companies to offer a
complete solution to the oncologist. ANGLE believes this is
the optimal approach for unlocking the multi-billion dollar
worldwide market available to the Company and its potential
strategic partners.
Partners will be selected for their specialist technical
capabilities enabling new high medical utility applications and/or
their market strength and existing installed base of diagnostic
systems enabling accelerated market adoption of the Parsortix
system.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We believe ANGLE's Parsortix system is the leading system for
harvesting circulating tumour cells from blood for analysis in
personalised cancer care. The combination of our system with
the Collaborator's single cell analysis system would produce a
powerful analytical capability, initially for researchers and
ultimately for clinicians creating a major commercial opportunity
for ANGLE."
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology, known as the Parsortix
system, harvests the cells of interest through a liquid biopsy,
with the patient only experiencing a simple blood test. Parsortix
is the subject of two granted US patents and three extensive
families of patents being progressed worldwide. The system is based
on a microfluidic device that captures cells based on a combination
of their size and compressibility. The Parsortix system is
established with strong positive evaluations from leading cancer
research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for
Europe and FDA authorisation is in
process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The Parsortix system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available
here http://www.angleplc.com/the-company/collaborators/
In addition to cancer, the Parsortix technology has the
potential for deployment with several other important cell types in
the future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the
ticker symbol AGL. For more information visit www.angleplc.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/angle-plc-angle-or-the-company-corporate-collaboration-with-large-pharmaceutical-company-300017774.html
SOURCE ANGLE plc